» Articles » PMID: 27023912

Glycosylation is Crucial for a Proper Catalytic Site Organization in Human Glucocerebrosidase

Overview
Journal Glycoconj J
Publisher Springer
Date 2016 Mar 30
PMID 27023912
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Gaucher disease, an autosomal recessive disorder, is caused by a deficiency of glucocerebrosidase (GCase) enzyme, a peripheral membrane-associated glycoprotein that hydrolyses glucosylceramide in lysosomes. Glycosylation is essential for the development of a catalytically active enzyme, specifically in the first site, located at Asn19. However, both the molecular basis of the relevance of N-glycosylation over GCase activity and the effects of glycosylation over its structure and dynamics are still not fully understood. Thus, the present work evaluated GCase enzyme in increasing glycosylation content using triplicate unbiased molecular dynamics simulations. Accordingly, the N-linked glycan chains caused local conformational stabilization effects over the protein, as well as in regions flanking the enzyme catalytic dyad. In the case of the Asn19-linked glycan, it also occurred around region 438-444, where one of the most prevalent GCase mutations is found. Markedly, an increasing catalytic dyad organization was related to increasing glycosylation contents, offering the first atomic-level explanation for the experimental observation that GCase activity is controlled by glycosylation, especially at Asn19.

Citing Articles

Lysophosphatidylcholine promoting α-Synuclein aggregation in Parkinson's disease: disrupting GCase glycosylation and lysosomal α-Synuclein degradation.

Mu C, Shao K, Su M, Guo Y, Qiu Y, Sun R NPJ Parkinsons Dis. 2025; 11(1):47.

PMID: 40089519 DOI: 10.1038/s41531-025-00902-7.


A PIKfyve modulator combined with an integrated stress response inhibitor to treat lysosomal storage diseases.

Hou W, Massey L, Rhoades D, Wu Y, Ren W, Frank C Proc Natl Acad Sci U S A. 2024; 121(34):e2320257121.

PMID: 39150784 PMC: 11348278. DOI: 10.1073/pnas.2320257121.


Glycosylation and Crowded Membrane Effects on Influenza Neuraminidase Stability and Dynamics.

Seitz C, Deveci I, McCammon J J Phys Chem Lett. 2023; 14(44):9926-9934.

PMID: 37903229 PMC: 10641874. DOI: 10.1021/acs.jpclett.3c02524.


Genetic variations in and genes: Biochemical and clinical consequences in Parkinson disease.

Smith L, Lee C, Menozzi E, Schapira A Front Neurol. 2022; 13:971252.

PMID: 36034282 PMC: 9416236. DOI: 10.3389/fneur.2022.971252.


Clinical Sphingolipids Pathway in Parkinson's Disease: From GCase to Integrated-Biomarker Discovery.

Esfandiary A, Finkelstein D, Voelcker N, Rudd D Cells. 2022; 11(8).

PMID: 35456032 PMC: 9028315. DOI: 10.3390/cells11081353.


References
1.
Brady R, KANFER J, Shapiro D . THE METABOLISM OF GLUCOCEREBROSIDES. I. PURIFICATION AND PROPERTIES OF A GLUCOCEREBROSIDE-CLEAVING ENZYME FROM SPLEEN TISSUE. J Biol Chem. 1965; 240:39-43. View

2.
Orwig S, Tan Y, Grimster N, Yu Z, Powers E, Kelly J . Binding of 3,4,5,6-tetrahydroxyazepanes to the acid-β-glucosidase active site: implications for pharmacological chaperone design for Gaucher disease. Biochemistry. 2011; 50(49):10647-57. PMC: 3235649. DOI: 10.1021/bi201619z. View

3.
Hruska K, Lamarca M, Scott C, Sidransky E . Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat. 2008; 29(5):567-83. DOI: 10.1002/humu.20676. View

4.
Tekoah Y, Tzaban S, Kizhner T, Hainrichson M, Gantman A, Golembo M . Glycosylation and functionality of recombinant β-glucocerebrosidase from various production systems. Biosci Rep. 2013; 33(5). PMC: 3782720. DOI: 10.1042/BSR20130081. View

5.
Lieberman R, Wustman B, Huertas P, Powe Jr A, Pine C, Khanna R . Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nat Chem Biol. 2006; 3(2):101-7. DOI: 10.1038/nchembio850. View